Furthermore, our current study suggests that MLCK expression, which may be induced by TNFR2 signaling in the intestinal epithelial cells, can be a therapeutic target for the maintenance of continuous inflammation and prevention of CAC development in the setting of IBD. The gene discussed is MYLK; the disease is inflammatory bowel disease.